Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HBI-2438 |
Synonyms | |
Therapy Description |
HBI-2438 selectively inhibits KRAS G12C, leading to decreased downstream signaling and potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (NCI Drug DIctionary, Mol Cancer Ther (2023) 22 (12_Supplement): A097). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HBI-2438 | HBI2438|HBI 2438 | KRAS G12C inhibitor 33 | HBI-2438 selectively inhibits KRAS G12C, leading to decreased downstream signaling and potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (NCI Drug DIctionary, Mol Cancer Ther (2023) 22 (12_Supplement): A097). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05485974 | Phase I | HBI-2438 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | Recruiting | USA | 1 |